These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37197631)

  • 1. Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101).
    Wang R; Shi M; Ji M; Han Z; Chen L; Liu Y; Lu K; Liu L; Chen B; Zhang X; Miao L; Shu Y
    Transl Lung Cancer Res; 2023 Apr; 12(4):786-796. PubMed ID: 37197631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).
    Xu CR; Chen Q; Zhou C; Wu L; Li W; Zhang H; Li Y; Xu F; Xiong J; Wang Q; Zhang H; Jiang Y; Yin H; Wu Q; Dai Q; Hu J; Chen J; Zhang J; Wu G; Yin J; Zhao J; Liu B; Shan J; Sheng L; Chen Q; Han Z; Shi H; Liu Y; Chen J; Wu YL
    Transl Lung Cancer Res; 2023 Jan; 12(1):127-140. PubMed ID: 36762057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
    Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
    Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
    Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
    Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
    Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
    Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
    Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
    Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer.
    Xu M; Meng X; Lu Y; Wang F
    J Gastrointest Oncol; 2022 Apr; 13(2):548-558. PubMed ID: 35557572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
    Xiang J; Gong W; Sun P; Wang X; Liu A
    J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety.
    Cao H; Wei W; Lu Y
    J Clin Pharm Ther; 2022 Nov; 47(11):1775-1782. PubMed ID: 35851702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.
    You R; Xu Q; Wang Q; Zhang Q; Zhou W; Cao C; Huang X; Ji H; Lv P; Jiang H; Lu Y; Jin Y; Li Y; Cheng L; Wang W; Xu H; Zhu X; Yin G
    Front Oncol; 2022; 12():816198. PubMed ID: 35982962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
    Li XP; Zhang WD; Li MJ; Wang J; Lian J; Zhou HG
    J Oncol; 2022; 2022():1710272. PubMed ID: 35909903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring
    Gao G; Ni J; Wang Y; Ren S; Liu Z; Chen G; Gu K; Zang A; Zhao J; Guo R; He J; Lin X; Pan Y; Ma Z; Wang Z; Fan M; Liu Y; Cang S; Yang X; Li W; Wang Q; Zhou C
    Transl Lung Cancer Res; 2022 Jun; 11(6):964-974. PubMed ID: 35832447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer.
    Huang Y; Wang J; Hu Y; Cao P; Wang G; Cai H; Wang M; Yang X; Wei Z; Ye X
    Front Oncol; 2022; 12():938827. PubMed ID: 36091128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial.
    Ren S; He J; Fang Y; Chen G; Ma Z; Chen J; Guo R; Lin X; Yao Y; Wu G; Wang Q; Zhou C
    JTO Clin Res Rep; 2022 May; 3(5):100312. PubMed ID: 35498381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
    Hou X; Shi X; Luo J
    Oncol Lett; 2022 Jul; 24(1):215. PubMed ID: 35720491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.